617 related articles for article (PubMed ID: 30955881)
1. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4
Binnewies M; Mujal AM; Pollack JL; Combes AJ; Hardison EA; Barry KC; Tsui J; Ruhland MK; Kersten K; Abushawish MA; Spasic M; Giurintano JP; Chan V; Daud AI; Ha P; Ye CJ; Roberts EW; Krummel MF
Cell; 2019 Apr; 177(3):556-571.e16. PubMed ID: 30955881
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
3. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
4. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
6. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H
J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
[TBL] [Abstract][Full Text] [Related]
8. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
Alderson KL; Zhou Q; Berner V; Wilkins DE; Weiss JM; Blazar BR; Welniak LA; Wiltrout RH; Redelman D; Murphy WJ
J Immunol; 2008 Mar; 180(5):2981-8. PubMed ID: 18292520
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
11. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
12. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
Watanabe S; Kagamu H; Yoshizawa H; Fujita N; Tanaka H; Tanaka J; Gejyo F
J Immunol; 2003 Dec; 171(11):5828-36. PubMed ID: 14634092
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses.
Bauman SK; Nichols KL; Murphy JW
J Immunol; 2000 Jul; 165(1):158-67. PubMed ID: 10861048
[TBL] [Abstract][Full Text] [Related]
14. Twist1 promotes dendritic cell-mediated antitumor immunity.
Luo Y; Chen J; Liu M; Chen S; Su X; Su J; Zhao C; Han Z; Shi M; Ma X; Huang H
Exp Cell Res; 2020 Jul; 392(2):112003. PubMed ID: 32278689
[TBL] [Abstract][Full Text] [Related]
15.
Sun XM; Guo K; Hao CY; Zhan B; Huang JJ; Zhu X
Cells; 2019 Nov; 8(11):. PubMed ID: 31703440
[No Abstract] [Full Text] [Related]
16. CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.
Matsuo K; Itoh T; Koyama A; Imamura R; Kawai S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
Cancer Lett; 2016 Aug; 378(1):16-22. PubMed ID: 27132989
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
18. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
19. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
20. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming.
Matheu MP; Othy S; Greenberg ML; Dong TX; Schuijs M; Deswarte K; Hammad H; Lambrecht BN; Parker I; Cahalan MD
Nat Commun; 2015 Feb; 6():6219. PubMed ID: 25653051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
